Masupirdine (mesylate)

$110$780

Products Details

Product Description

– Masupirdine mesylate (SUVN-502 mesylate) is a potent, selective, orally bioavailable, and brain penetrant 5-HT6 receptor antagonist (Ki of 2.04 nM for human 5-HT6 receptor). Masupirdine mesylate (SUVN-502 mesylate) shows high selectivity over 5-HT2A receptor and other 100 target sites, and has potential for treatment of Alzheimer’s disease[1].

Web ID

– HY-109118A

Storage Temperature

– 4°C (Powder, sealed storage, away from moisture)

Shipping

– Room Temperature

Applications

– Neuroscience-Neurodegeneration

Molecular Formula

– C23H32BrN3O9S3

References

– [1]Nirogi R, et al. Discovery and Development of 1-[(2-Bromophenyl)sulfonyl]-5-methoxy-3-[(4-methyl-1-piperazinyl)methyl]-1H-indole Dimesylate Monohydrate (SUVN-502): A Novel, Potent, Selective and Orally Active Serotonin 6 (5-HT6) Receptor Antagonist for Potential Treatment of Alzheimer’s Disease. J Med Chem. 2017 Mar 9;60(5):1843-1859.

CAS Number

– 1791396-46-7

Molecular Weight

– 670.61

Compound Purity

– 99.62

SMILES

– CS(=O)(O)=O.O=S(N1C2=CC=C(OC)C=C2C(CN3CCN(C)CC3)=C1)(C(C=CC=C4)=C4Br)=O.CS(=O)(O)=O

Clinical Information

– Phase 3

Research Area

– Neurological Disease

Solubility

– DMSO : 25 mg/mL (ultrasonic)

Target

– 5-HT Receptor

Isoform

– 5-HT6 Receptor

Pathway

– GPCR/G Protein;Neuronal Signaling

Product type

– Reference compound

Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.

My Cart
Close Wishlist
Close Recently Viewed
Categories

Please fill out this form to request the file. We will send it to your Email address shortly. Thanks.

Please enable JavaScript in your browser to complete this form.

=

Please fill out this form to request the pricing.
We will send it to your email address shortly.
Thanks.

Please enable JavaScript in your browser to complete this form.

=